Thesis: Better Diagnostic Resolution
Biotech's New Year's Resolution
Wes and I would like to thank Dr. Oliver Bathe for contextualizing the clinical role of diagnostics and Zac Fernandes for the critical review of the work before publishing. A special thank you to members of the diagnostics community for the thoughtful discussions.
The central dogma of biotechnology is that therapeutics are more valuable than diagnostics. We think we should flip that on its head. Diagnostics are the silent champion of healthcare, influencing >60% of clinical decisions but only accounting for 2-4% of healthcare spend. Any additional investments would yield large returns for healthcare systems and patients.
—Andrew Hui & Wes Keelan
1. Pathology is limited by overgeneralized stratification
2. Diagnostics are critical but remain a fraction of healthcare spend
3. The trajectory of therapeutics and diagnostics are converging
4. Biomarkers are transitioning from simple to complex
5. Simple and scalable applications of standardized data in healthcare have been massively rewarded
6. Strong biomarkers compress biological complexity
7. Network medicine is the ultimate expression of convergence
8. Diagnostics must continuously measure network states, not just detect individual molecules
9. Diagnostic accessibility limits the evolution of disease management
10. Diagnostic innovation may be the key to breaking Eroom’s Law
Disclaimer: The information in this post is not intended to be and does not constitute investment or financial advice. You should not make any decision based on the information presented without conducting independent due diligence.
 | A guest post by
|